Elastrin Therapeutics, a privately held biotechnology company, has closed a USD10 million funding round led by Kizoo Technology Capital, an early-stage investor in breakthrough rejuvenation technologies.
Other investors in the round include Starbloom Capital and SC Launch.
Elastrin Therapeutics was founded in 2018 as a spinout from Clemson University where the technology was first developed over a 20-year period. The company’s lead asset ELT-001 is an EDTA-loaded nanoparticle conjugated with a proprietary monoclonal antibody for the treatment of vascular calcification.
